Cargando…

The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution

Improvements in the outcomes of elderly multiple myeloma (MM) patients have lagged behind those of transplant‐eligible patients, likely due in part to the use of less efficacious melphalan‐containing regimens. To date, there are very limited data for the outcomes of elderly MM patients in the United...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonomo, Lauren, Lue, Jerry, Jagannath, Sundar, Chari, Ajai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799960/ https://www.ncbi.nlm.nih.gov/pubmed/26799254 http://dx.doi.org/10.1002/cam4.620

Ejemplares similares

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2021)

Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2010)

Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
por: Bhalla, Sherry, et al.
Publicado: (2021)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study
por: Chari, Ajai, et al.
Publicado: (2016)

The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia
por: Liu, Chia‐Jen, et al.
Publicado: (2020)

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect(®) MM Registry
por: Lee, Hans C., et al.
Publicado: (2021)

Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant
por: Ailawadhi, Sikander, et al.
Publicado: (2022)

The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors
por: Paul, Barry, et al.
Publicado: (2020)

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2018)

Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients
por: Bao, Li, et al.
Publicado: (2020)

Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy
por: Merola, David, et al.
Publicado: (2018)

Front‐line treatment patterns in multiple myeloma: An analysis of U.S.‐based electronic health records from 2011 to 2019
por: Kumar, Shaji, et al.
Publicado: (2021)

Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
por: Gu, Jingli, et al.
Publicado: (2021)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies
por: Lancman, Guido, et al.
Publicado: (2018)

Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model
por: Bloudek, Lisa, et al.
Publicado: (2016)

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience
por: Bertoli, Sarah, et al.
Publicado: (2019)

Thirty-Year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes
por: Fang, Michael, et al.
Publicado: (2021)

Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients
por: Lin, Wen‐Ying, et al.
Publicado: (2022)

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
por: Theodoropoulos, Nicholas, et al.
Publicado: (2020)

MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21(Cip1)
por: Mei, Anna Huo-Chang, et al.
Publicado: (2020)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
por: Sborov, Douglas W., et al.
Publicado: (2022)

Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients
por: Belch, Andrew, et al.
Publicado: (2020)

Comparison of efficacy, safety, patients’ quality of life, and doctors’ occupational stress between lenalidomide‐based and bortezomib‐based induction in patients with newly diagnosed multiple myeloma
por: Xu, Limei, et al.
Publicado: (2021)

Highly variable trends in rates of newly diagnosed HIV cases in U.S. hotspots, 2008-2017
por: Segarra, Lorena, et al.
Publicado: (2021)

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
por: Pan, Darren, et al.
Publicado: (2021)

Associations between cancer and Alzheimer's disease in a U.S. Medicare population
por: Freedman, Daryl Michal, et al.
Publicado: (2016)

Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice
por: Rupa‐Matysek, Joanna, et al.
Publicado: (2018)

Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib‐based combination therapy: A real‐world experience of off‐label ibrutinib use
por: Chen, Feili, et al.
Publicado: (2020)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c4fal9uar9p4ui1b1g7btql3mj